In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.

Yang, Philip; Tekwani, Seema; Martin, Greg S

Yang, Philip; Tekwani, Seema; Martin, Greg S.

Yang P; Emory University, Atlanta, Georgia, USA (P.Y., S.T., G.S.M.).
Tekwani S; Emory University, Atlanta, Georgia, USA (P.Y., S.T., G.S.M.).
Martin GS; Emory University, Atlanta, Georgia, USA (P.Y., S.T., G.S.M.).

Ann Intern Med ; 172(12): JC63, 2020 06 16.

Article in English | MEDLINE | ID: covidwho-599919

ABSTRACT

ABSTRACT

SOURCE CITATION Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;3821787-99. 32187464.

Subject(s)

Pneumonia, Viral; Ritonavir; Adult; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Lopinavir; Pandemics; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Ritonavir Type of study: Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Ann Intern Med Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google